Netta Blondheim-Shraga, PhD
Netta Blondheim-Shraga, PhD is the Vice President of Research & Development at BrainsStorm. She is responsible for advancing the company’s pipeline and steering the R&D team toward significant breakthroughs in the field of cell therapy and the development of novel solutions to positively impact patients’ health. Dr. Blondheim-Shraga, was part of the research team at Tel Aviv University that developed the NurOwn® technology platform and led the preclinical development NurOwn® for ALS in its early years. She rejoins BrainStorm with over 14 years of translational research experience in academic, biotech, and pharma settings, having led teams in Israel, USA and China, combining scientific, entrepreneurial, and management skills.
Prior to rejoining BrainStorm, Dr. Blondheim-Shraga was Project Leader on the Academic Affairs team at Teva Pharmaceuticals, Israel. In this scientific scouting and advising role, she managed a portfolio of diverse and highly impactful strategic scientific collaborations with Teva’s academic partners. Prior to Teva, she was Study Director and Senior Scientist at CrownBio, San Diego, CA. Earlier in her career, she was a Senior Scientist at Lifemap Sciences LTD in Tel-Aviv and served as Scientific Advisor to ImmunoHiTech LTD, Ramat Hasharon, Israel for several years. Dr. Blondheim-Shraga received a PhD from the Faculty of Medicine, Bar-Ilan University, Safed, Israel, an MSc from The Faculty of Medicine, Tel Aviv University, Israel and a BSc from The Faculty of Medicine, Hebrew University Jerusalem, Israel.